SA07280062B1 - الاجسام المضادة لـ il -22 الآدمى و استخداماتها - Google Patents

الاجسام المضادة لـ il -22 الآدمى و استخداماتها Download PDF

Info

Publication number
SA07280062B1
SA07280062B1 SA07280062A SA07280062A SA07280062B1 SA 07280062 B1 SA07280062 B1 SA 07280062B1 SA 07280062 A SA07280062 A SA 07280062A SA 07280062 A SA07280062 A SA 07280062A SA 07280062 B1 SA07280062 B1 SA 07280062B1
Authority
SA
Saudi Arabia
Prior art keywords
antibody
sequence
ser
gly
ala
Prior art date
Application number
SA07280062A
Other languages
Arabic (ar)
English (en)
Inventor
سوزان إي. كوهين
ديفيد سي. لوي
دافيندر اس. جيل
لينيت إية. فورز
جيرترويدا ام. فيلدمان
جينغ لي
رالف آر. مينتر
فييا فالجي ـ آرشر
كارولين إس. رسل
البيرت جي. ثوم
Original Assignee
ويث
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38236225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA07280062(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ويث filed Critical ويث
Publication of SA07280062B1 publication Critical patent/SA07280062B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SA07280062A 2006-02-21 2007-02-21 الاجسام المضادة لـ il -22 الآدمى و استخداماتها SA07280062B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77459606P 2006-02-21 2006-02-21

Publications (1)

Publication Number Publication Date
SA07280062B1 true SA07280062B1 (ar) 2012-03-13

Family

ID=38236225

Family Applications (1)

Application Number Title Priority Date Filing Date
SA07280062A SA07280062B1 (ar) 2006-02-21 2007-02-21 الاجسام المضادة لـ il -22 الآدمى و استخداماتها

Country Status (31)

Country Link
US (4) US7901684B2 (enExample)
EP (3) EP3020729B1 (enExample)
JP (1) JP5150516B2 (enExample)
KR (2) KR101616712B1 (enExample)
CN (1) CN101426816B (enExample)
AR (1) AR059604A1 (enExample)
AT (1) ATE538137T1 (enExample)
AU (1) AU2007217751B2 (enExample)
BR (1) BRPI0708101B8 (enExample)
CA (1) CA2643226C (enExample)
CR (1) CR10237A (enExample)
DK (2) DK3020729T3 (enExample)
EC (1) ECSP088751A (enExample)
ES (2) ES2738731T3 (enExample)
HN (1) HN2008001292A (enExample)
HU (1) HUE044595T2 (enExample)
IL (1) IL193605A (enExample)
MX (2) MX2008010708A (enExample)
MY (1) MY146664A (enExample)
NO (1) NO20083715L (enExample)
NZ (1) NZ570878A (enExample)
PE (1) PE20080111A1 (enExample)
PL (2) PL3020729T3 (enExample)
PT (2) PT1991584E (enExample)
RU (1) RU2467016C2 (enExample)
SA (1) SA07280062B1 (enExample)
SG (1) SG172628A1 (enExample)
SI (2) SI1991584T1 (enExample)
TW (1) TWI417301B (enExample)
WO (1) WO2007098170A1 (enExample)
ZA (1) ZA200807278B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ515678A (en) * 1999-04-28 2004-01-30 Genetics Inst Human GIL-19/AE289 proteins and polynucleotides encoding same
JP2009518314A (ja) * 2005-12-02 2009-05-07 ジェネンテック・インコーポレーテッド Ｉｌ−２２に結合する抗体およびｉｌ−２２ｒに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
KR20110048536A (ko) * 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도
EP2419733A4 (en) 2009-04-13 2013-12-25 Univ Leland Stanford Junior METHOD AND DEVICES FOR DETECTING THE PRESENCE OF AN ANALYZES IN A SAMPLE
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
EP2545367B1 (en) 2010-03-12 2022-02-09 The Board of Trustees of the Leland Stanford Junior University Magnetic sensor based quantitative binding kinetics analysis
US20120114652A1 (en) * 2010-05-03 2012-05-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
US9221904B2 (en) * 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
AU2013310924B2 (en) * 2012-08-31 2017-08-03 Argenx Bvba Method for producing antibody molecules having inter-species, intra-target cross-reactivity
PL2970422T3 (pl) 2013-03-15 2018-09-28 F.Hoffmann-La Roche Ag Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania
CN105139918B (zh) * 2015-06-26 2017-04-12 哈尔滨工业大学 一种柔板印刷用低银高性能导电浆料及其制备方法
CN105601739B (zh) * 2016-02-22 2019-01-18 王晨辉 一种人源化抗白介素22基因工程抗体及其应用
WO2018039107A1 (en) * 2016-08-22 2018-03-01 Medimmune, Llc Binding molecules specific for notch4 and uses thereof
EP3546943A4 (en) * 2016-11-24 2020-09-16 Huvet Bio, Inc. DIAGNOSIS OF DISEASES
CA3041279A1 (en) 2016-11-28 2018-05-31 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
AU2017364818C1 (en) 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
KR20250134208A (ko) 2017-11-28 2025-09-09 추가이 세이야쿠 가부시키가이샤 항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
KR102536314B1 (ko) * 2018-05-23 2023-05-25 주식회사 휴벳바이오 질환의 진단용 조성물
MX2020013243A (es) 2018-06-05 2021-05-12 Bioatla Inc Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos.
CN113825495A (zh) * 2018-10-11 2021-12-21 阿利维奥治疗学股份有限公司 用于智能释放的不可注射水凝胶调配物
EP3981428A4 (en) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha Protease substrate, and polypeptide including protease cleavage sequence
CN115943210A (zh) 2020-01-20 2023-04-07 中外制药株式会社 配体结合融合蛋白
KR102226826B1 (ko) * 2020-08-06 2021-03-11 주식회사 휴벳바이오 버피 코트 시료에 사용하기 위한 췌장암 진단용 조성물
BR112023008265A2 (pt) 2020-12-07 2024-02-06 UCB Biopharma SRL Anticorpos contra interleucina-22
US20240067758A1 (en) * 2020-12-07 2024-02-29 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
KR20230165212A (ko) 2021-03-02 2023-12-05 다나-파버 캔서 인스티튜트 인크. 적혈구 장애의 치료 방법
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9214857D0 (en) 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5674487A (en) * 1994-09-28 1997-10-07 Univ Jefferson Method for treating autoimmune diseases
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
AU2576697A (en) * 1996-04-19 1997-11-12 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing anti-il-8 antibody as active ingredient
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
US6492507B1 (en) * 1996-10-23 2002-12-10 Incyte Genomics, Inc. Polynucleotides encoding human eosinophil-derived basic protein
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US20030032057A1 (en) * 1997-08-26 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002016611A2 (en) 2000-08-24 2002-02-28 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6551799B2 (en) * 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6350892B1 (en) 1997-09-23 2002-02-26 Bristol-Myers Squibb Company Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
KR100764256B1 (ko) * 1998-01-23 2007-10-05 에프. 호프만-라 로슈 아게 인간 인터루킨-12에 대한 항체
JP2002516103A (ja) 1998-05-29 2002-06-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド インターロイキン２１およびインターロイキン２２
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
US6331613B1 (en) * 1998-10-26 2001-12-18 Ludwig Institue For Cancer Research Isolated nucleic acid molecules which encode T cell inducible factors (TIFS), the proteins encoded, and uses thereof
US7081528B2 (en) * 1998-10-26 2006-07-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding T cell derived inducible factors
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
BR0009323A (pt) 1999-03-25 2002-01-08 Knoll Gmbh Anticorpos humanos que ligam a il-12 humana e métodos para a produção
US7307161B1 (en) * 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
JP2002543840A (ja) 1999-05-19 2002-12-24 インサイト・ゲノミックス・インコーポレイテッド 細胞外シグナル伝達分子
AU5047600A (en) 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
JP2003529324A (ja) 1999-06-15 2003-10-07 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードする核酸
CA2393369A1 (en) * 1999-12-03 2001-06-07 Zymogenetics, Inc. Human cytokine receptor
EP2194130A1 (en) 1999-12-23 2010-06-09 ZymoGenetics, L.L.C. Cytokine ZCYTO18
US20030170823A1 (en) * 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
AU2001233034A1 (en) 2000-01-27 2001-08-07 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
SK12942002A3 (sk) * 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
US20030012788A1 (en) * 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
CA2416820A1 (en) 2000-07-27 2002-02-07 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
US7094570B2 (en) * 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2005510451A (ja) 2001-02-23 2005-04-21 ジェネティクス インスティテュート，エルエルシー 炎症性障害を治療するための組成物及び方法
US7638604B2 (en) * 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20020187512A1 (en) 2001-09-10 2002-12-12 Nagem Ronaldo Alves Pinto Crystal structure of human interleukin-22
EP1546358A4 (en) 2002-03-22 2006-06-07 Zymogenetics Inc ANTI-IL-TIF ANTIBODIES AND METHOD FOR USE ON INFLAMMATION
ATE518884T1 (de) * 2002-05-01 2011-08-15 Human Genome Sciences Inc Spezifisch an chemokin beta-4 bindende antikörper
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
KR20060022289A (ko) * 2003-06-23 2006-03-09 제네틱스 인스티튜트, 엘엘씨 인터류킨-22 에 대한 항체 및 그의 용도
CA2612746A1 (en) 2005-07-04 2007-01-11 Samsung Electronics Co., Ltd. Position measuring system and method using wireless broadband (wibro) signal
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation

Also Published As

Publication number Publication date
EP1991584A1 (en) 2008-11-19
HK1120813A1 (en) 2009-04-09
RU2008134137A (ru) 2010-03-27
RU2467016C2 (ru) 2012-11-20
MY146664A (en) 2012-09-14
BRPI0708101A8 (pt) 2019-01-22
EP3020729A1 (en) 2016-05-18
ES2377463T3 (es) 2012-03-27
JP5150516B2 (ja) 2013-02-20
ECSP088751A (es) 2008-11-27
CA2643226A1 (en) 2007-08-30
WO2007098170A1 (en) 2007-08-30
BRPI0708101B1 (pt) 2020-01-14
BRPI0708101B8 (pt) 2021-05-25
NO20083715L (no) 2008-11-06
KR20080113214A (ko) 2008-12-29
ES2738731T3 (es) 2020-01-24
US20130005033A1 (en) 2013-01-03
US8182817B2 (en) 2012-05-22
PT3020729T (pt) 2019-08-06
TW200801041A (en) 2008-01-01
IL193605A (en) 2015-07-30
US7901684B2 (en) 2011-03-08
MX2008010708A (es) 2008-11-14
US8187603B2 (en) 2012-05-29
AU2007217751A1 (en) 2007-08-30
KR20140100589A (ko) 2014-08-14
HUE044595T2 (hu) 2019-11-28
BRPI0708101A2 (pt) 2011-05-17
EP1991584B1 (en) 2011-12-21
ATE538137T1 (de) 2012-01-15
TWI417301B (zh) 2013-12-01
IL193605A0 (en) 2011-08-01
SI1991584T1 (sl) 2012-05-31
US20100184960A1 (en) 2010-07-22
CA2643226C (en) 2016-04-12
AR059604A1 (es) 2008-04-16
PE20080111A1 (es) 2008-02-20
DK3020729T3 (da) 2019-07-29
JP2009531023A (ja) 2009-09-03
US20110275790A1 (en) 2011-11-10
MX337778B (es) 2016-03-18
PT1991584E (pt) 2012-02-20
CR10237A (es) 2008-11-26
PL1991584T3 (pl) 2012-05-31
US8470993B2 (en) 2013-06-25
HN2008001292A (es) 2012-02-13
ZA200807278B (en) 2009-05-27
EP2431392B1 (en) 2015-09-09
PL3020729T3 (pl) 2019-12-31
SG172628A1 (en) 2011-07-28
DK1991584T3 (da) 2012-04-02
EP2431392A1 (en) 2012-03-21
NZ570878A (en) 2011-09-30
KR101616712B1 (ko) 2016-04-29
CN101426816A (zh) 2009-05-06
SI3020729T1 (sl) 2019-10-30
CN101426816B (zh) 2012-12-12
AU2007217751B2 (en) 2012-08-23
EP3020729B1 (en) 2019-06-26
US20070243589A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
JP6959390B2 (ja) Ｂ細胞成熟化抗原を標的化する抗体および使用の方法
JP7158403B2 (ja) Ｂ７－ｈ３抗体、その抗原結合フラグメント、及びそれらの医学的使用
US11555077B2 (en) 4-1BB antibody and preparation method and use thereof
TWI840399B (zh) 結合人il-4r的抗體、其抗原結合片段及其醫藥用途
JP2022033256A (ja) Ｆｃ受容体様５を標的とする抗体および使用方法
KR101815265B1 (ko) FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
CN110267989B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CA3285038A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
CN115109156B (zh) 一种靶向bcma的纳米抗体及其应用
SG172628A1 (en) Antibodies against human il-22 and uses therefor
CA3032783C (en) Antibody to programmed cell death 1 (pd-1) and use thereof
BR112019016356A2 (pt) anticorpo anti-sirpg humano ou fragmento de ligação de antígeno do mesmo ou mimético de anticorpo de ligação de antígeno, produto de combinação, método in vitro ou ex vivo, uso de pelo menos um anticorpo anti-sirpg de humano ou fragmento de ligação de antígeno do mesmo ou mimético de anticorpo de ligação ao antígeno, e, método in vitro de prever a resposta de um sujeito a um tratamento
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
CA2724915A1 (en) Interleukin-21 receptor binding proteins
KR102939584B1 (ko) 인간 cd47-표적화 단일-도메인 항체 및 그 사용
TWI889920B (zh) 抗ｔｒｏｐ-２抗體、其抗原結合片段或其突變體、及其醫藥用途
WO2022078490A1 (zh) 抗erbb3抗体或其抗原结合片段及其医药用途
KR20210125885A (ko) Cd73의 면역관문을 억제하기 위한 항체 및 이의 용도
CA3150462A1 (en) Anti-cd19 antibodies and uses thereof
CN110734494A (zh) 抗tspan8单克隆抗体及其用途
CN116478288A (zh) 红细胞弱结合型人源化cd47抗体及其应用
KR20170076332A (ko) 항 Ang2 항체를 포함하는 면역강화제
HK40076989B (en) Anti-cd22 antibodies and uses thereof
KR20220150384A (ko) Areg에 대한 항체 및 그 용도
HK40036076B (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof